A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

• Status: Recruiting
• Trial end date: 2025-03-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Famotidine; Peginterferon alfa-2a

Criteria

Inclusion Criteria:

• Healthy male and female (i e, women not of childbearing potential) participants

• Body Mass Index (BMI) of 18 to 32 kg^m2 and total body weight ≥ 50 kg

• Parts A, B, and D: Participants without restriction on ethnicity

• Part C: Participants of Japanese ethnicity (both biological parents are ethnically Japanese)

Exclusion Criteria:

• Clinically significant medical, psychiatric and/or sound social reason, as determined by the investigator

• Any major surgery within 3 months of study intervention administration

• Participation in another clinical trial concurrent with this study

Note: Other protocol-defined inclusion/exclusion criteria apply